In the Japanese Pediatric Leukemia/Lymphoma Study Group trial MLL-10, by introducing intensive chemotherapy, the indication of HSCT was restricted to patients with high-risk (HR) features only (KMT2A-r and either age <180 days or the presence of central nervous system leukemia). This evidence concerns the gene KMT2A and leukemia.